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Abstract
Objective: Relapse	of	AML	after	allogeneic	hematopoietic	stem	cell	transplantation	
(HSCT)	has	a	poor	prognosis,	and	standard	of	care	therapy	is	lacking.	Early	(<6	months)	
relapse	is	associated	with	dismal	outcome,	while	the	majority	of	relapses	occur	early	
after	 transplantation.	A	more	precise	 indication	which	patients	could	benefit	 from	
reinduction	therapy	is	warranted.
Methods: We	retrospectively	analyzed	outcomes	of	83	patients	with	postallogeneic	
HSCT	 relapse.	Patients	were	divided	based	on	 intention	 to	 treat	 (curative	vs	 sup‐
portive	care).
Results: Of	the	50	patients	treated	with	curative	intent,	44%	reached	complete	re‐
mission	(CR)	upon	reinduction	chemotherapy,	and	of	these	patients,	50%	survived.	
Two	survivors	 reached	CR	after	 immunotherapy	 (donor	 lymphocyte	 infusion	 (DLI),	
without	reinduction	chemotherapy).	Sixty‐nine	percent	of	the	survivors	had	received	
high‐intensity	cytarabine	treatment,	followed	by	immunologic	consolidation.	Relapse	
<3	months	after	transplantation	was	predictive	for	adverse	survival	(P	=	.004),	but	
relapse	<6	months	was	not.	In	fact,	>50%	of	the	survivors	had	a	relapse	<6	months.
Conclusion: We	 confirmed	 the	 dismal	 prognosis	 of	 postallogeneic	 HSCT	 relapse.	
Importantly,	 our	 data	 demonstrate	 that	 patients	 fit	 enough	 to	 receive	 high‐dose	
chemotherapy,	 even	 when	 relapse	 occurred	 <6	 months,	 had	 the	 best	 chance	 to	
obtain	 durable	 remissions,	 in	 particular	when	 immunologic	 consolidation	was	 per‐
formed	after	reaching	CR.
K E Y W O R D S
acute	myeloid	leukemia,	allogeneic	hematopoietic	stem	cell	transplantation,	graft‐versus‐
leukemia,	outcome
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
33
91
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9
2  |     JONG et al.
1  | INTRODUC TION
Allogeneic	hematopoietic	stem	cell	transplantation	(HSCT)	is	the	pre‐
ferred	treatment	for	patients	with	(MRD	positive)	intermediate‐risk	
or	poor‐risk	acute	myeloid	leukemia	(AML)	and	high‐risk	myelodys‐
plastic	syndrome	(MDS).	While	transplant	related	mortality	has	de‐
creased,	the	risk	for	relapse	has	not.	Disease	relapse	is	a	common	and	
important	cause	of	the	poor	long‐term	survival	of	allogeneic	HSCT	
recipients	with	AML.	Relapse	accounts	for	30%‐40%	of	deaths	after	
allogeneic	HSCT,	depending	on	 the	 type	of	 the	donor	and	disease	
status	 at	 transplant.1,2	 Prognosis	 of	 postallogeneic	HSCT	AML	 re‐
lapse	is	poor3,4	and	has	hardly	improved	in	the	past	decades.	There	is	
no	standard	of	care	for	patients	who	relapse	after	allogeneic	HSCT.	
Age	 (<37	 year)	 and	 a	 longer	 time	 (>5	months)	 between	 allogeneic	
HSCT	and	relapse	have	been	identified	as	favorable	prognostic	fac‐
tors.3,5,6	Other	factors	such	as	clinical	condition	and	personal	consid‐
erations	of	the	patient	may	be	weighed	in	the	decision	to	either	give	
supportive	care,	offer	low‐dose	chemotherapy,	or	attempt	high‐dose	
reinduction	chemotherapy.	In	reality,	curative	treatment	options	are	
often	limited,	and	in	many	cases,	it	can	be	more	appropriate	to	refrain	
from	intensive	treatment	regimens	and	opt	for	best	supportive	care.
Most	 AML	 relapses	 occur	 in	 the	 first	 6	months	 after	 allogeneic	
HSCT,	a	period	during	which	many	patients	still	receive	immunosup‐
pressive	therapy.	Rapid	tapering	of	immunosuppression	can	potentially	
lead	to	the	initiation	of	a	graft‐versus‐leukemia	(GvL)	effect	and	remis‐
sion	of	 leukemia.7‐9	When	patients	 relapse	after	 cessation	of	 immu‐
nosuppressive	therapy	or	when	tapering	of	immunosuppression	does	
not	result	in	remission,	hypomethylating	therapy	such	as	azacitidine	or	
decitabine	may	be	used	to	induce	remission.	Hypomethylating	agents	
have,	apart	from	their	direct	anti‐leukemic	effects,	immunomodulatory	
properties,10,11	for	example	through	natural	killer	(NK)	cells,	potentially	
augmenting	 GvL	 responses.	 In	 a	 small	 group	 of	 patients	 with	 AML	
or	MDS	relapse	after	allogeneic	HSCT,	azacitidine	 induced	complete	
remission,	and	about	50%	of	these	patients	had	prolonged	(>2	years)	
disease‐free	survival.12	 If	 the	clinical	condition	of	 the	patient	allows,	
high‐dose	 chemotherapy	 can	 be	 tried	 in	 order	 to	 achieve	 complete	
remission.1,13	The	decision	of	physician	and	patient	to	treat	or	refrain	
from	 treatment	 is	 a	 difficult	 consideration	 between	 chance	 of	 cure	
with	the	risk	of	severe	debilitating	side	effects	and	indivertible	death	
in	the	setting	of	end	of	life	care	that	is	aimed	at	maximizing	comfort.
Complete	remission	after	reinduction	chemotherapy	can	be	con‐
solidated	by	(re‐)inducing	a	GvL	response,	most	often	via	donor	lym‐
phocyte	infusions	(DLI).	DLI	can	be	very	effective	in	inducing	lasting	
GvL	responses	after	postallogeneic	HSCT	AML	relapse.3,14	However,	
in	case	of	cord	blood	transplantation	DLI	is	unavailable,	and	not	all	
patients	are	eligible	for	DLI	as	it	may	re‐induce	or	exacerbate	graft‐
versus‐host	disease	(GvHD).	In	case	of	an	early	detected	molecular	
or	cytogenetic	 relapse,	DLI	can	be	performed	without	 reinduction	
therapy.	Alternatively,	a	second	allogeneic	HSCT	with	a	new	donor	
can	be	performed.	DLI	or	a	second	allogeneic	HSCT	is	most	success‐
ful	in	female	patients	with	a	late	relapse	(>6	months)	of	cytogeneti‐
cally	favorable	AML	and	when	DLI	is	given	once	complete	remission	
is	achieved.1‐3,14
In	this	study,	we	retrospectively	analyzed	outcomes	of	patients	
with	 postallogeneic	 HSCT	 AML	 relapse,	 in	 whom	 the	 decision	 to	
offer	curative	or	best	supportive	care	therapy	was	based	on	factors	
described	above,	 a	per‐patient	 analysis	of	physical	 fitness	 and	co‐
morbidity,	and	individual	considerations	of	the	patient.
2  | PATIENTS AND METHODS
2.1 | Patients
The	medical	 records	of	 all	 83	 adult	 patients	 (>17	years	of	 age)	with	
myeloid	 malignancies	 who	 had	 received	 an	 allogeneic	 HSCT	 at	 the	
Amsterdam	 University	 Medical	 Centers	 between	 January	 1,	 2010,	
and	December	31,	2016,	and	 in	whom	disease	relapse	occurred	be‐
fore	December	31,	2017,	were	reviewed.	Eighty	of	these	patients	were	
diagnosed	with	AML,	and	three	patients	underwent	allogeneic	HSCT	
for	chronic	myelomonocytic	leukemia	(CMMoL)	or	high‐risk	myelodys‐
plastic	syndrome	(MDS	with	excess	of	blasts	(EB)	II).	Patients	were	clas‐
sified	according	to	the	WHO	Classification	of	myeloid	neoplasms	and	
acute	leukemia	2008	(hereafter	WHO	2008	Classification).15	Risk	was	
defined	according	to	the	risk	group	classification	used	in	the	then	active	
HOVON	92,	HOVON	102,	and	HOVON	132	trials	(Table	S1)	in	which	
most	patients	participated.	The	few	patients	not	participating	in	these	
trials	were	classified	and	treated	according	these	trials.	This	prognostic	
classification	 is	based	on	known	risk	factors	with	respect	to	cytoge‐
netic	abnormalities	and	molecular	alterations,	white	blood	cell	count	
(WBC),	and	attainment	of	early	complete	remission.	The	cytogenetic	
abnormalities	and	molecular	alterations	that	were	used	for	the	risk	as‐
sessment	of	these	patients	are	in	line	with	the	prognostic	risk	groups	of	
the	European	Leukemia	Net	2010.16	Six	patients	received	one	or	more	
prophylactic	donor	lymphocyte	infusions	(DLI)	after	allogeneic	HSCT,	
before	relapse.	Immunologic	consolidation	with	consecutive	DLI	was	
started	at	 least	6	weeks	after	recovery	form	chemotherapy‐induced	
neutropenia.	 In	accordance	with	the	Declaration	of	Helsinki,	written	
informed	consent	was	obtained	from	all	patients.
2.2 | Statistical analysis
The	 collected	 data	 were	 coded	 and	 anonymously	 processed.	 The	
analyses	 were	 done	 using	 IBM	 SPSS	 Statistics	 24.0.0.1	 software.	
Patient	characteristics	were	compared	using	Mann‐Whitney	U	tests	
in	 case	 of	 continuous	 variable,	 and	 the	 chi‐square	 test	 or	 Fisher's	
exact	 test	were	used	to	compare	categorical	variables.	For	 the	or‐
dinal	 variable	 prognostic	 class,	 both	 Pearson's	 r	 and	 Kendall's	 tau	
were	determined.	Survival	differences	were	evaluated	using	Kaplan‐
Meier	analysis	and	compared	by	using	the	log‐rank	test.
3  | RESULTS
3.1 | Patient characteristics
Demographics	 of	 the	 83	 patients	who	 had	 received	 an	 allogeneic	
HSCT	 for	 AML	 or	 high‐risk	 MDS	 between	 January	 1,	 2010	 and	
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December	31,	2016,	and	 relapsed	before	December	31,	2017,	are	
shown	 in	Table	1.	Three	patients	 (4%)	who	had	been	 initially	clas‐
sified	 as	 good	 risk	 had	 received	 an	 allogeneic	 HSCT	 because	 of	
relapsed	AML.	Four	of	the	patients	had	an	intracranial	or	leptome‐
ningeal	localization	of	their	relapse,	and	no	AML	blasts	in	the	bone	
marrow.	 Median	 time	 of	 follow‐up	 for	 survivors	 was	 220	 weeks,	
ranging	from	49	to	391	weeks.
3.2 | Curative treatment vs best supportive care
Patients	were	classified	into	two	groups:	patients	who	were	treated	
with	curative	intent	(CIT	group)	and	patients	who	refrained	from	cu‐
rative	 treatment	 and	 received	best	 supportive	 care	 either	 at	 their	
own	 request	 or	 as	 advised	 by	 the	 treating	 physician	 (BSC	 group).	
Treatment	with	 curative	 intent	was	 considered	 in	 all	 patients	 that	
were	 fit	 enough	 according	 to	 the	 treating	 physician,	 in	 particular	
when	relapse	occurred	more	than	6	months	after	allogeneic	HSCT.	
Despite	 the	 fact	 that	 relapse	 less	 than	 6	months	 after	 allogeneic	
HSCT	is	considered	a	very	poor	prognostic	factor,	11	patients	with	
such	an	early	 relapse	 received	 reinduction	 chemotherapy,	 in	most	
cases	 because	of	 young	 age,	 excellent	 clinical	 condition,	 and	 very	
high	motivation	 of	 the	 patient.	 The	 decision	 to	 treat	 or	 to	 refrain	
from	curative	treatment	was	always	made	after	extensive	elabora‐
tion	between	physicians	and	in	close	consultation	with	the	patient	
and	his/her	family.
Fifty	(60%)	of	the	patients	were	treated	with	curative	intent	of	
which	13	(26%)	were	still	alive	at	the	end	of	follow‐up	(16%	of	all	pa‐
tients	in	this	study;	Table	2).	Patients	in	the	CIT	group	were	younger	
than	BSC	patients	(median	53	vs	58	years,	P	=	.043),	had	significantly	
lower	 bone	marrow	 blast	 counts	 (median	 21%	 vs	 38%,	P	 =	 .025),	
and	had	lower	cytogenetical/molecular	risk	characteristics	(r	=	.226;	
P	=	.040;	Table	2).	When	excluding	the	relapses	that	were	restricted	
to	 the	 central	 nervous	 system,	 no	 significant	 difference	 in	 bone	
marrow	blast	count	was	observed	between	the	BSC	and	CIT	groups	
(median	38%	vs	24%,	P	=	.082).	No	differences	could	be	assessed	for	
the	WHO	2008	Classification	as	 the	 subgroups	were	 too	 small	 to	
properly	evaluate.	The	time	between	allogeneic	HSCT	and	relapse	
ranged	from	3	to	63	weeks	for	the	BSC	group	and	5‐187	weeks	for	
the	CIT	group.	Overall,	prognosis	was	very	poor,	with	a	2‐year	sur‐
vival	of	17%	for	the	whole	group	(Figure	1).	Median	time	of	survival	
was	16	weeks	for	the	CIT	group	and	only	3	weeks	for	the	best	sup‐
portive	care	group	(Table	2).
In	the	CIT	group,	two	patients	(4%)	with	low	blast	counts	(8%	and	
10%,	respectively)	received	DLI	without	reinduction	therapy,	in	23	
patients	(46%)	immunosuppressants	were	tapered	and	stopped,	10	
patients	(20%)	were	treated	with	a	hypomethylating	agent,	of	whom	
3	(6%)	received	this	agent	as	single	treatment,	and	22	patients	(44%)	
were	treated	with	high‐dose	chemotherapy.	High‐dose	chemother‐
apy	consisted	of	high‐dose	cytarabine	in	the	majority	of	cases,	and	
FLAG	 (fludarabine,	 cytarabine,	 G‐CSF)	 or	 other	 regimens	 in	 the	
other	patients	(Table	S2).	Four	patients	had	an	isolated	central	ner‐
vous	 system	 relapse	with	 intracranial	 chloroma	or	 leptomeningeal	
AML	localization.	These	patients	were	in	the	CIT	group	and	received	
TA B L E  1  Patient	characteristics
Characteristic All patients (N = 83)
Outcome—no.	(%)
Deceased 70	(84)
Survive 13	(16)
Sex—no.	(%)
Male 46	(55)
Female 37	(45)
Age	at	time	of	allogeneic	HSCT—y
Median	(interquartile	range) 54	(47‐62)
Range 18‐71
Prognostic	class	at	time	of	AML	diagnosis—no.	(%)
Good	risk 3	(4)
Intermediate	risk 19	(23)
Poor	risk 35	(42)
Very	poor	risk 26	(31)
WHO	classification—no.	(%)
AML	with	recurrent	genetic	
abnormalities
33	(40)
AML	with	myelodysplasia‐related	
changes
9	(11)
Therapy‐related	myeloid	neoplasms 6	(7)
AML	NOS 32	(39)
Other 3	(4)
HSCT	donor—no.	(%)
MUD	(10/10) 53	(64)
SIB 28	(34)
CB 2	(2)
Conditioning	regimen—no.	(%)
Myeloablative 8	(10)
Reduced	intensity 71	(85)
FLAMSA 4	(5)
Bone	marrow	blast	count	at	time	of	relapse—%	(N	=	74)
Median	(interquartile	range) 25	(14‐52.25)
Range 0† ‐99
Time	between	allogeneic	HSCT	and	relapse—wk
Median	(interquartile	range) 21	(12‐32)
Range 3‐187
Very	early	vs	late	relapse—no.	(%)
Very	early	(<3	mo) 23	(28)
Late	(≥3	mo) 60	(72)
Early	vs	late	relapse—no.	(%)
Early	(<6	mo) 52	(63)
Late	(≥6	mo) 31	(37)
Intention	to	treat—no.	(%)
Curative 50	(60)
Palliative	(best	supportive	care) 33	(40)
†Four	patients	had	an	isolated	central	nervous	system	relapse.	
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TA B L E  2  Patient	characteristics	of	best	supportive	care	and	curative‐intent	groups
Characteristic Curative (n = 50)
Best supportive care 
(n = 33)  
Outcome—no.	(%)
Deceased 37	(74) 33	(100)  
Survived 13	(26) 0	(0)
Sex—no.	(%)
Male 29	(58) 17	(48.5) P	=	.561
Female 21	(42) 16	(51.5)
Age	at	time	of	allogeneic	HSCT—y
Median	(interquartile	range) 53	(39‐58) 58	(50‐64) P = .043
Range 18‐71 26‐68
Prognostic	class	at	time	of	AML	diagnosis—no.	(%)
Good	risk 2	(4) 1	(3) Pearson's	r	=	.226;	P = .040
Intermediate	risk 15	(30) 4	(12)
Poor	risk 21	(42) 14	(42)
Very	poor	risk 12	(24) 14	(42)
WHO	classification—no.	(%)
AML	with	recurrent	genetic	
abnormalities
19	(38) 14	(42)  
AML	with	myelodysplasia‐related	
changes
5	(10) 4	(12)
Therapy‐related	myeloid	
neoplasms
3	(6) 3	(9)
AML	NOS 21	(42) 11	(33)
Other 2	(4) 1	(3)
Transplantation	type—no.	(%)
MUD	(10/10) 31	(62) 22	(67)  
SIB 8	(36) 10	(30)
CB 1	(2) 1	(3)
Conditioning	regimen—no.	(%)
Myeloablative 7	(14) 1	(3) P = .137
Reduced	intensity	or	FLAMSA 43	(86) 32	(97)
Bone	marrow	blast	count	at	time	of	relapse—%	(n	=	74)
Median	(interquartile	range) 21	(10‐50) 38	(20‐67) P	=	.025† 
Range 0‐74 10‐99
No	data 4 5  
Time	between	allogeneic	HSCT	and	relapse—wk
Median	(interquartile	range) 21	(14‐47) 21	(6‐28) P = .047
Range 5‐187 3‐63
Early	vs	late	relapse—no.	(%)
Early	(<3	mo) 11	(22) 12	(36) P = .119
Late	(≥3	mo) 39	(78) 21	(64)
Time	between	relapse	and	death—wk
Median	(interquartile	range) 16	(6‐31) 3	(1‐10) P	<	.001
Range 2‐119 0‐37
†When	n	=	4	patients	with	isolated	CNS	relapse	are	excluded,	the	difference	in	bone	marrow	blast	counts	between	the	two	groups	is	not	significant.	
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intrathecal	cytarabine,	in	some	combined	with	systemic	cytarabine,	
intrathecal	 methotrexate,	 or	 radiotherapy.	 Two	 of	 these	 patients	
attained	complete	remission	and	were	alive	at	6.5	and	7.5	years	after	
their	relapse.	DLI	is	given	as	consolidation	therapy	to	those	patients	
that	obtained	complete	remission.	Most	patients	that	did	not	receive	
consolidation	with	DLI	had	rapid	progression	of	the	disease	and/or	
failing	of	reinduction	therapy.	For	2	patients,	the	donor	was	not	(cord	
blood	HSCT)	or	no	longer	available;	the	rest	of	the	patients	did	not	
receive	DLI	because	of	GvHD.
3.3 | Determinants of survival
The	CIT	group	was	then	split	into	survivors	and	non‐survivors,	as	per	
end	of	follow‐up	(December	31,	2017),	in	order	to	identify	prognos‐
tic	relevant	differences	between	these	two	groups	(Figure	2).	In	one	
patient,	AML	 relapsed	 after	 she	 had	 obtained	 complete	 remission	
following	reinduction	 therapy	with	curative	 intent	 (tapering	of	 im‐
munosuppressants	followed	by	hypomethylating	therapy).	This	pa‐
tient	was	still	alive	but	with	active	AML	at	the	end	of	follow‐up	and	
therefore	evaluated	in	the	survivor	group	(Table	S2, patient ID_030). 
There	was	no	difference	in	age,	type	of	transplantation,	condition‐
ing	regimen,	bone	marrow	blast	percentage	at	time	of	relapse	or	the	
time	between	 transplantation,	 and	 relapse	between	 survivors	 and	
non‐survivors.	 However,	 survivors	 had	more	 often	 received	 high‐
dose	reinduction	chemotherapy	(69%	vs	35%,	P	=	.035)	and	immu‐
nologic	 consolidation	 therapy	 (69%	 vs	 22%,	P	 =	 .003;	 Table	 3).	 In	
addition,	survivors	had	more	often	reached	complete	remission	after	
F I G U R E  1  Overall	survival.	Survival	curve	of	the	entire	patient	
cohort	(n	=	83).	One‐year	survival	was	23%,	and	2‐y	survival	was	
17%
F I G U R E  2  Curative‐intent	group.	
Representation	of	patients	in	the	curative‐
intent	treatment	group	divided	into	
patients	reaching	complete	remission	or	
not.	*Group	containing	one	patient	who	
was	alive	at	the	end	of	follow‐up	despite	
relapse	after	re‐obtaining	complete	
remission.	CR,	complete	remission;	No	
cons:	no	immunologic	consolidation;	PD,	
progressive	disease
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reinduction	therapy,	whereas	this	was	only	the	case	for	a	minority	of	
the	non‐survivors	(85%	vs	30%,	P	=	.001).	Together,	the	CR	rate	after	
reinduction	therapy	was	22/50	(44%),	of	whom	10	survived	without	
relapse	(Figure	2),	which	is	in	line	with	published	studies.3,4,12,17	Five	
patients	received	immunologic	consolidation	therapy	(four	patients	
DLI,	 one	 patient	 second	 allogeneic	 HSCT),	 despite	 not	 obtaining	
complete	 remission,	 and	 two	of	 them	 survived	 (one	who	 received	
DLI	and	the	patient	who	received	2nd	allogeneic	HSCT).	Estimated	
median	survival	time	of	patients	who	did	not	reach	complete	remis‐
sion	upon	 reinduction	 therapy	was	9	weeks	vs	119	weeks	 for	 the	
patients	that	did	(Figure	3A).	Survival	was	significantly	better	for	the	
patients	who	 relapsed	more	 than	3	months	after	allogeneic	HSCT	
compared	with	those	who	relapsed	within	3	months	after	allogeneic	
HSCT	 (P	 =	 .004;	 Figure	 3B).	When	 relapse	within	 6	months	 after	
TA B L E  3  Patient	characteristics	of	survivors	and	non‐survivors	in	the	curative‐intent	group
Characteristic Non‐survivors (n = 37) Survivors (n = 13)  
Sex—no.	(%)
Male 21	(57) 8	(62) P	=	.764
Female 16	(43) 5	(39)
Age	at	time	of	allogeneic	HSCT—y
Median	(interquartile	range) 53	(39‐60) 53	(36‐59) P	=	.674
Range 18‐71 22‐62
Age	at	time	of	relapse—y
Median	(interquartile	range) 53	(40‐60) 53	(38‐60) P = .707
Range 19‐74 22‐62
Bone	marrow	blast	count	at	time	of	relapse—%	(n	=	46)
Median	(interquartile	range) 20	(14‐51) 22	(8‐49) P	=	.745
Range 1‐72 0‐74
No	data 3 1  
Reinduction	therapy—no.	(%)
No	reinduction	therapy 1	(3) 1	(8)  
Hypomethylating	therapy	only 3	(8) 0	(0)
High‐dose	chemotherapy 13	(35) 9	(69)
Reduce/stop	immunosuppressants 20	(54) 3	(23)
Reinduction	therapy—no.	(%)
No/low‐intensity	therapy 24	(65) 4	(31) P	=	.035
High‐intensity 13	(35) 9	(69)
Outcome	after	reinduction	therapy—no.	(%)
CR 11	(30) 11	(85) P = .001
No	CR 26	(70) 2	(15)
Hypomethylating	agents—no.	(%)
Yes 7	(19) 3	(23) P	=	.533
No 29	(81) 10	(77)
No	data 1   
Consolidation	therapy
No	consolidation	therapy 29	(78) 4	(31) P = .003
Consolidation	therapy 8	(22) 9† 	(69)
Time	between	HSCT	and	relapse—wk
Median	(interquartile	range) 21	(12‐46) 21	(17‐59) P = .479
Range 5‐142 11‐187
Early	vs	late	relapse—no.	(%)
Early	(<3	mo) 10	(27) 1	(8) P = .144
Late	(≥3	mo) 27	(73) 12	(92)
†Two	received	a	second	allogeneic	HSCT	with	a	different	donor,	the	other	patients	DLI.	
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allogeneic	HSCT	 vs	 after	 6	months	was	 taken	 as	 a	 cutoff,	 no	 sig‐
nificant	difference	in	survival	was	observed.	In	fact,	7	of	the	12	dis‐
ease‐free	survivors	had	received	reinduction	therapy	despite	early	
(<6	months	after	allogeneic	HSCT)	relapse	(Table	S2).	The	size	of	the	
patient	group	did	not	allow	for	outcome	analyses	of	molecular	and	
cytogenetic	risk	groups.
4  | DISCUSSION
Patients	with	relapsed	AML	or	MDS	after	allogeneic	HSCT	have	a	
dismal	prognosis.	 It	 remains	 a	 challenge	 to	 identify	 those	patients	
that	 may	 benefit	 from	 curative‐intent	 salvage	 therapy	 when	 best	
supportive	care	in	reality	is	probably	most	appropriate	for	the	major‐
ity	of	patients.	Selection	of	patients	for	either	best	supportive	care	
or	curative‐intent	therapy	 is	generally	based	on	the	physician's	as‐
sessment	of	the	patient's	chances	of	survival,	his/her	fitness,	and	the	
wish	of	the	patient.	Predictors	for	survival,	as	described	in	literature,	
including	time	from	allogeneic	HSCT	to	relapse,	patient	age	and	sex,	
cytogenetics,	blast	count	at	diagnosis	of	relapse,	and	remission	status	
at	immunologic	consolidation	(DLI	or	2nd	allogeneic	HSCT)	are	also	
taken	into	consideration.3,4,12,14,18‐23	In	this	retrospective	analysis	of	
a	 non‐preselected	 patient	 group	with	 relapse	 of	AML	or	 high‐risk	
MDS	after	allogeneic	HSCT,	we	attempted	to	 identify	 factors	 that	
should	be	 taken	 into	account	when	considering	 treatment	options	
for	individual	patients.	We	could	confirm	the	very	poor	prognosis	of	
relapsed	AML	after	allogeneic	HSCT.	The	2‐year	survival	of	only	17%	
in	patients	with	relapsed	AML	after	allogeneic	HSCT	is	in	line	with	
other	 studies	 (Figure	1).17,18	Outcome	was	best	 for	 those	patients	
who	were	fit	enough	to	receive	high‐dose	reinduction	therapy	fol‐
lowed	by	 immunologic	consolidation	therapy	with	DLI	or	2nd	allo‐
geneic	HSCT	in	complete	remission.	We	confirmed	previous	reports	
showing	that	time	between	allogeneic	HSCT	and	relapse	was	signifi‐
cantly	correlated	with	survival,	with	very	early	relapses	(<3	months)	
having	a	dismal	prognosis.3,4,19,20	Most	 importantly,	we	 found	that	
early	 relapse,	between	3	and	6	months	after	allogeneic	HSCT,	did	
not	have	a	worse	prognosis	compared	with	relapse	>6	months	after	
allogeneic	HSCT.	This	finding	is	of	clinical	significance,	as	the	major‐
ity	of	relapses	occurs	within	6	months	after	allogeneic	HSCT.	Given	
that	2nd	relapses	may	occur	 late,	but	always	sooner	 than	the	first	
relapse,	 it	 is	 important	 to	 have	 a	 sufficient	 period	 of	 follow‐up	 in	
order	to	identify	the	long‐term	survivors.	With	a	median	time	of	fol‐
low‐up	of	over	4	years,	which	was	longer	than	the	initial	time	period	
between	allogeneic	HSCT	and	relapse	in	all	but	one	patient,	we	are	
confident	 that	 the	patients	 that	we	qualified	as	non‐relapse	survi‐
vors	are	likely	to	be	cured.
Previous	analyses	on	survival	after	relapse	focused	on	patients	
treated	 with	 curative	 intent	 only,	 inherently	 containing	 the	 risk	
of	 selection	 bias.	 In	 our	 study,	 we	 included	 all	 patients	 with	 re‐
lapsed	AML	or	high‐risk	MDS	after	allogeneic	HSCT	in	our	center.	
Comparison	of	the	CIT	and	BSC	groups,	defined	based	on	intention	
to	 treat,	 revealed	 that	patients	who	according	 to	 their	physicians	
did	not	qualify	for	curative‐intent	therapy	or	choose	to	refrain	from	
intensive	therapy	(the	latter	being	a	minority	of	cases)	were	a	little	
older	(53	[range	18‐71]	vs	58	[26‐68]	years,	P	=	.04)	and	had	higher	
rates	of	very	poor‐risk	AML	at	primary	diagnosis	(Table	2).	Age	was	
not	 significantly	 different	 between	 survivors	 and	 non‐survivors	
of	 patients	 treated	with	 curative	 intent,	while	 the	 curative‐intent	
group	had	a	higher	age	 range.	Blast	 count	at	diagnosis	of	 relapse	
was	not	 significantly	 associated	with	outcome	within	 the	CIT	pa‐
tient	group,	and	due	to	the	size	of	the	patient	group,	we	could	not	
F I G U R E  3  Survival	of	best	supportive	care	and	curative‐intent	
groups,	and	of	early	vs	late	relapse.	A,	The	curative‐intent	group	
was	grouped	into	patients	that	did	and	did	not	reach	complete	
remission	(CR)	after	reinduction	therapy.	Patients	treated	with	
curative	intent,	who	reached	CR	after	reinduction	therapy,	have	
significantly	better	survival	than	the	two	other	groups.	B,	Survival	
curves	for	patients	with	early	vs	late	relapse	with	early	relapse	
defined	as	relapse	within	3	mo	after	allogeneic	HSCT
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correlate	cytogenetics	with	survival.	The	absence	of	a	correlation	
between	survival	and	age	or	bone	marrow	blast	count	is	in	contrast	
to	other	studies3,20	and	may	be	related	to	the	lower	number	of	pa‐
tients	 in	our	 study.	The	majority	of	patients	 received	 reduced‐in‐
tensity	conditioning	(RIC).	Nevertheless,	survivor	and	non‐survivor	
groups	in	our	analysis	both	contained	young	and	old	patients,	with	
low	 and	 higher	 amounts	 of	 bone	marrow	 blasts.	 Together,	 these	
data	 suggest	 that	 fitness	 rather	 than	 age,	 blast	 count,	 or	 time	 of	
relapse	(except	when	<3	months	after	allogeneic	HSCT)	should	be	
taken	 into	 account	when	 considering	 patients	 for	 remission	 rein‐
duction	therapy.
We	 confirm	 previous	 reports	 demonstrating	 that	 re‐ob‐
taining	 complete	 remission	 is	 an	 important	 prognostic	 determi‐
nant.3,4,20‐22,24	Only	2	of	the	28	patients	that	did	not	reach	complete	
remission	 after	 curative‐intent	 therapy	 survived	 (Figure	 2	 and	
Table	3),	while	85%	of	the	survivors	had	obtained	complete	remis‐
sion	after	reinduction	therapy.	Remission	can	be	induced	using	dif‐
ferent	strategies.	The	strength	of	the	GvL	effect	is	underlined	by	the	
observation	that	cessation	of	 immunosuppressants	alone	 (without	
subsequent	 hypomethylating	 agents	 or	 high‐dose	 chemotherapy)	
led	to	remission	of	AML	in	5	out	of	18	patients	(28%).	Cessation	of	
immunosuppressants	 in	combination	with	hypomethylating	agents	
led	 to	CR	 in	 two	out	of	 five	patients.	None	of	 the	 five	 remaining	
patients	receiving	hypomethylating	therapy	(stand‐alone	or	in	com‐
bination	with	other	therapies)	obtained	complete	remission.	These	
results	are	 in	 line	with	 the	15%‐19%	complete	 remission	 rates	 re‐
ported	after	hypomethylating	 therapy	 in	 literature.12,25	 In	a	direct	
(retrospective)	comparison,	high‐dose	chemotherapy	was	more	ef‐
fective	than	reinduction	therapy	with	hypomethylating	agents,	 in‐
ducing	complete	remission	in	40%	vs	7%	of	patients,	respectively.26 
Also	in	our	cohort,	high‐dose	therapy	was	most	successful	in	induc‐
ing	 complete	 remission,	with	 75%	 of	 patients	 obtaining	 complete	
remission	following	high‐dose	reinduction	chemotherapy.	It	should	
be	noted	that	the	patients	treated	with	these	more	intensive	salvage	
therapies	were	the	fittest	patients	with	initially	the	best	estimated	
prognosis,	most	likely	contributing	to	the	better	outcome	of	these	
patients.
Equally	 important	 and	 challenging	 is	 the	maintenance	 of	 com‐
plete	 remission.	Of	 the	 12	 patients	who	 after	 obtaining	 complete	
remission	 received	 immunological	 consolidation,	 most	 often	 DLI,	
and	 in	 one	 case	 second	 allogeneic	HSCT,	 seven	 patients	 survived	
(58%).	 In	contrast,	only	30%	of	the	patients	who	reached	CR,	but,	
due	to	varying	reasons,	could	not	proceed	to	 immunologic	consol‐
idation,	 survived	 (Figure	 2).	 AML	 relapse	 after	 allogeneic	HSCT	 is	
associated	with	a	dysregulation	in	immune	function	pathways	such	
as	HLA	expression	by	AML	blasts	 that	may	help	AML	 cells	 evade	
donor	 immune	 responses.27	 Immunologic	 consolidation	 can	be	 ef‐
fective	when	newly	infused	donor	immune	cells	that	are	naive	with	
regard	 to	 the	 patient's	AML	elicit	 a	GvL	 response	 independent	 of	
HLA‐related	antigen	presentation,	 for	example,	 to	 targets	 that	are	
expressed	on	the	membrane	of	AML	blasts.28,29	Thus,	as	also	sug‐
gested	 by	 other	 studies,	 immunological	 consolidation	 is	 of	 impor‐
tance	 for	 survival	 in	 this	 setting.	GvHD	occurred	 in	 some	but	not	
all	surviving	patients	suggesting	that	immunologic	consolidation	can	
also	be	effective	when	it	does	not	lead	to	GvHD.3
With	 new	 therapies	 for	 AML	 emerging,	 the	 arsenal	 to	 treat	
AML	relapse	after	allogeneic	HSCT	is	expanding.	The	Bcl2	inhibitor	
Venetoclax	in	combination	with	hypomethylating	agents	has	shown	
promising	results	 in	patients	with	relapsed	or	refractory	AML.30	A	
wide	range	of	mutation‐targeting	agents	is	available,	most	of	them	
tyrosine‐kinase	inhibitors	directed	against	FLT3.31	Adoptive	transfer	
of	natural	killer	(NK)	cells	and	T	cells	targeting	AML‐specific	antigens	
are	under	investigation,	and	chimeric	antigen	receptor	(CAR)	T	cells	
and	bispecific	T‐cell	engagers	targeting	CD33	and	CD123	are	being	
developed.13,32	Prospective	clinical	trials	are	required	to	investigate	
the	potential	of	these	novel	therapies	in	the	treatment	of	AML	re‐
lapse	after	allogeneic	HSCT.
Taken	 together,	while	 relapsed	AML	and	MDS	after	 allogeneic	
HSCT	have	a	dismal	prognosis,	a	subset	of	patients	may	benefit	from	
curative‐intent	therapy.	Selection	of	candidates	remains	a	challenge	
and	should	be	based	on	patient's	fitness	as	determined	by	the	team	
of	 treating	physicians	and	on	 the	motivation	of	 the	patient.	 In	pa‐
tients	deemed	fit,	reinduction	therapy	may	offer	a	prospect	for	cure.	
Our	data	suggest	that	more	patients	might	be	eligible	for	intensive	
reinduction	 treatment	 than	 previously	 assumed	 as	 time	 between	
transplantation	 and	 relapse	 should	 only	 be	 taken	 into	 account	 in	
case	of	very	early	relapses,	for	example,	<3	months	after	allogeneic	
HSCT,	 in	which	 case	 outcome	 is	 dismal.	 Reinduction	 therapy	 that	
fails	may	prolong	life	expectancy	but	most	often	at	the	expense	of	
quality	of	 life.	 If	complete	remission	is	obtained,	however,	chances	
for	cure	improve	significantly,	in	particular	when	immunologic	con‐
solidation	therapy	to	reinvigorate	or	redirect	GvL	responses	is	given.
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